Endo International (NASDAQ:ENDP) Issues Q2 Earnings Guidance

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) issued an update on its second quarter earnings guidance on Thursday morning. The company provided EPS guidance of $(0.17)-(0.15) for the period, compared to the consensus EPS estimate of $0.48. The company issued revenue guidance of $500-525 million, compared to the consensus revenue estimate of $655.56 million.

ENDP stock traded down $0.68 during midday trading on Friday, hitting $1.34. The company’s stock had a trading volume of 365,995 shares, compared to its average volume of 4,868,811. The company’s fifty day moving average price is $2.36 and its 200 day moving average price is $3.63. Endo International has a twelve month low of $1.92 and a twelve month high of $7.07. The stock has a market capitalization of $313.12 million, a P/E ratio of -0.52 and a beta of 1.07.

Endo International (NASDAQ:ENDPGet Rating) (TSE:ENL) last announced its quarterly earnings data on Thursday, May 5th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.22. Endo International had a negative return on equity of 90.96% and a negative net margin of 20.49%. The company had revenue of $652.26 million for the quarter, compared to analysts’ expectations of $637.09 million. During the same quarter in the prior year, the business posted $0.73 EPS. The business’s revenue was down 9.1% compared to the same quarter last year. As a group, equities research analysts forecast that Endo International will post 1.7 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on ENDP. Citigroup dropped their target price on shares of Endo International from $11.00 to $6.00 and set a buy rating on the stock in a report on Wednesday, March 9th. Piper Sandler cut their price objective on Endo International from $5.00 to $3.00 and set a neutral rating for the company in a research report on Wednesday, March 2nd. Barclays downgraded Endo International from an equal weight rating to an underweight rating and cut their price target for the company from $5.00 to $2.00 in a report on Wednesday, March 2nd. StockNews.com initiated coverage on shares of Endo International in a report on Thursday, March 31st. They issued a hold rating on the stock. Finally, TheStreet downgraded shares of Endo International from a c- rating to a d rating in a report on Wednesday, February 2nd. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of Hold and a consensus price target of $4.79.

Several hedge funds and other institutional investors have recently modified their holdings of ENDP. Parametric Portfolio Associates LLC raised its stake in Endo International by 108.1% in the fourth quarter. Parametric Portfolio Associates LLC now owns 871,726 shares of the company’s stock valued at $3,278,000 after purchasing an additional 452,778 shares in the last quarter. Geode Capital Management LLC increased its holdings in Endo International by 11.0% in the 4th quarter. Geode Capital Management LLC now owns 4,280,507 shares of the company’s stock valued at $16,094,000 after buying an additional 425,177 shares during the period. Bank of New York Mellon Corp raised its position in shares of Endo International by 4.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,163,896 shares of the company’s stock valued at $7,012,000 after buying an additional 97,708 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Endo International by 106.0% during the 4th quarter. Marshall Wace LLP now owns 183,794 shares of the company’s stock worth $691,000 after acquiring an additional 94,595 shares during the period. Finally, California State Teachers Retirement System increased its stake in Endo International by 2.1% in the fourth quarter. California State Teachers Retirement System now owns 320,848 shares of the company’s stock valued at $1,206,000 after acquiring an additional 6,572 shares during the last quarter. Institutional investors own 80.39% of the company’s stock.

About Endo International (Get Rating)

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology.

Read More

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.